|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Tadalafil#Adverse Reactions]] |
| {{Tadalafil}}
| |
| {{CMG}}; {{AE}} {{PB}}
| |
| | |
| '''''For patient information, click <u>[[Tadalafil tablet (patient information)|here]]'''''</u>
| |
| | |
| ==Adverse Reactions==
| |
| The following serious adverse reactions are discussed elsewhere in the labeling:
| |
| | |
| * [[Hypotension]] [see Warnings and Precautions (5.1)]
| |
| * Vision loss [see Warnings and Precautions (5.5)]
| |
| * Hearing loss [see Warnings and Precautions (5.6)]
| |
| * [[Priapism]] [see Warnings and Precautions (5.8)]
| |
| ===Clinical Trials Experience===
| |
| | |
| Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
| |
| | |
| Tadalafil was administered to 398 patients with [[PAH]] during clinical trials worldwide. In trials of ADCIRCA, a total of 311 and 251 subjects have been treated for at least 182 days and 360 days, respectively. The overall rates of discontinuation because of an adverse event (AE) in the placebo-controlled trial were 9% for ADCIRCA 40 mg and 15% for placebo. The rates of discontinuation because of AEs, other than those related to worsening of [[PAH]], in patients treated with ADCIRCA 40 mg was 4% compared to 5% in placebo-treated patients.
| |
| | |
| In the placebo-controlled study, the most common AEs were generally transient and mild to moderate in intensity. Table 1 presents treatment-emergent adverse events reported by ≥9% of patients in the ADCIRCA 40 mg group and occurring more frequently than with placebo.
| |
| | |
| {|
| |
| |-
| |
| |[[Image:Tadanafil1.PNG|thumb|800px]]
| |
| |-
| |
| |}
| |
| | |
| ===Postmarketing Experience===
| |
| | |
| The following adverse reactions have been identified during post-approval use of tadalafil. These events have been chosen for inclusion either because of their seriousness, reporting frequency, lack of clear alternative causation, or a combination of these factors. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure. The list does not include adverse events that are reported from clinical trials and that are listed elsewhere in this section.
| |
| | |
| * Cardiovascular and cerebrovascular — Serious cardiovascular events, including [[myocardial infarction]], [[sudden cardiac death]], [[stroke]], chest pain, palpitations, and [[tachycardia]], have been reported postmarketing in temporal association with the use of tadalafil. Most, but not all, of these patients had preexisting cardiovascular risk factors. Many of these events were reported to occur during or shortly after sexual activity, and a few were reported to occur shortly after the use of tadalafil without sexual activity. Others were reported to have occurred hours to days after the use of tadalafil and sexual activity. It is not possible to determine whether these events are related directly to tadalafil, to sexual activity, to the patient's underlying cardiovascular disease, to a combination of these factors, or to other factors [see Warnings and Precautions (5.1)].
| |
| | |
| * Body as a whole — [[Hypersensitivity]] reactions including [[urticaria]], Stevens–Johnson syndrome, and [[exfoliative dermatitis]]
| |
| | |
| * Nervous — [[Migraine]], [[seizure]] and seizure recurrence, and transient global amnesia
| |
| | |
| * Ophthalmologic — Visual field defect, [[retinal vein occlusion]], and retinal artery occlusion
| |
| | |
| * Non–arteritic anterior [[ischemic optic neuropathy]] (NAION), a cause of decreased vision including permanent loss of vision, has been reported rarely postmarketing in temporal association with the use of [[PDE5]] inhibitors, including tadalafil. Most, but not all, of these patients had underlying anatomic or vascular risk factors for development of NAION, including but not necessarily limited to: low cup to disc ratio (“crowded disc”), age over 50, [[diabetes]], [[hypertension]], [[coronary artery disease]], [[hyperlipidemia]], and [[smoking]]. It is not possible to determine whether these events are related directly to the use of [[PDE5]] inhibitors, to the patient's underlying vascular risk factors or anatomical defects, to a combination of these factors, or to other factors [see Warnings and Precautions (5.5) and Patient Counseling Information (17)].
| |
| | |
| * Otologic — Cases of sudden decrease or loss of hearing have been reported postmarketing in temporal association with the use of [[PDE5]] inhibitors, including tadalafil. In some of the cases, medical conditions and other factors were reported that may have also played a role in the otologic adverse events. In many cases, medical follow-up information was limited. It is not possible to determine whether these reported events are related directly to the use of tadalafil, to the patient's underlying risk factors for hearing loss, a combination of these factors, or to other factors [see Warnings and Precautions (5.6) and Patient Counseling Information (17)].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ADCIRCA (TADALAFIL) TABLET [UNITED THERAPEUTICS CORPORATION] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ff61b237-be8e-461b-8114-78c52a8ad0ae | publisher = | date = | accessdate = 7 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Drugs]]
| |